RU2757723C2 - Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита - Google Patents

Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита Download PDF

Info

Publication number
RU2757723C2
RU2757723C2 RU2020125098A RU2020125098A RU2757723C2 RU 2757723 C2 RU2757723 C2 RU 2757723C2 RU 2020125098 A RU2020125098 A RU 2020125098A RU 2020125098 A RU2020125098 A RU 2020125098A RU 2757723 C2 RU2757723 C2 RU 2757723C2
Authority
RU
Russia
Prior art keywords
bgag
vlp
protein
virus
vaccine
Prior art date
Application number
RU2020125098A
Other languages
English (en)
Russian (ru)
Other versions
RU2020125098A3 (enExample
RU2020125098A (ru
Inventor
Питер Пушко
Ирина Третьякова
Original Assignee
Медиджен, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Медиджен, Инк. filed Critical Медиджен, Инк.
Publication of RU2020125098A publication Critical patent/RU2020125098A/ru
Publication of RU2020125098A3 publication Critical patent/RU2020125098A3/ru
Application granted granted Critical
Publication of RU2757723C2 publication Critical patent/RU2757723C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/866—Baculoviral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04—Inactivation or attenuation; Producing viral sub-units
    • C12N7/045—Pseudoviral particles; Non infectious pseudovirions, e.g. genetically engineered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/14011—Deltaretrovirus, e.g. bovine leukeamia virus
    • C12N2740/14034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
    • C12N2740/15051—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
RU2020125098A 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита RU2757723C2 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562188084P 2015-07-02 2015-07-02
US62/188,084 2015-07-02

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2018103757A Division RU2734118C2 (ru) 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Publications (3)

Publication Number Publication Date
RU2020125098A RU2020125098A (ru) 2020-09-04
RU2020125098A3 RU2020125098A3 (enExample) 2020-12-11
RU2757723C2 true RU2757723C2 (ru) 2021-10-21

Family

ID=57609369

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020125098A RU2757723C2 (ru) 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
RU2018103757A RU2734118C2 (ru) 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2018103757A RU2734118C2 (ru) 2015-07-02 2016-07-01 Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита

Country Status (13)

Country Link
US (2) US11576965B2 (enExample)
EP (1) EP3316906A4 (enExample)
JP (2) JP6978079B2 (enExample)
KR (1) KR20180032586A (enExample)
CN (2) CN108348596B (enExample)
BR (1) BR112018000037A2 (enExample)
CA (1) CA2991213A1 (enExample)
EA (1) EA201890187A1 (enExample)
MA (1) MA42312A (enExample)
MX (1) MX390927B (enExample)
PE (1) PE20180771A1 (enExample)
RU (2) RU2757723C2 (enExample)
WO (1) WO2017004586A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine
CN112279900A (zh) * 2020-12-30 2021-01-29 乾元浩生物股份有限公司 H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN113403343A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备
CN113398259A (zh) * 2021-04-30 2021-09-17 吉林大学 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335139D1 (de) * 2002-05-17 2011-01-05 Univ Emory Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
RU2535365C2 (ru) * 2007-05-29 2014-12-10 Кристофер Б РЕЙД Способы получения и применения мультипотентных клеточных популяций
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6864085B2 (en) 1999-12-14 2005-03-08 Novartis Ag Bovine immunodeficiency virus (BIV) based vectors
WO2004042001A2 (en) * 2002-05-17 2004-05-21 Emory University Virus-like particles, methods of preparation, and immonogenic compositions
US8506967B2 (en) * 2003-07-11 2013-08-13 Novavax, Inc. Functional influenza virus like particles (VLPs)
WO2008005777A2 (en) 2006-06-30 2008-01-10 Novavax, Inc. Methods of enhancing protein incorporation into virus like particles
WO2008094200A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
US20100247574A1 (en) 2007-02-21 2010-09-30 Kutub Mahmood CHIMERIC NEWCASTLE DISEASE VIRUS VLPs
AU2008275895A1 (en) * 2007-07-19 2009-01-22 Novavax, Inc. Varicella Zoster Virus-virus like particles (VLPS) and antigens
WO2011087839A1 (en) * 2009-12-22 2011-07-21 Baxter International Inc. Vaccine to influenza a virus
US20110293700A1 (en) * 2010-05-26 2011-12-01 Selecta Biosciences, Inc. Nanocarrier compositions with uncoupled adjuvant
US20140004146A1 (en) * 2011-03-17 2014-01-02 Institut Pasteur Of Shanghai, Chinese Academy Of Sciences Method for producing virus-like particle by using drosophila cell and applications thereof
MA42312A (fr) * 2015-07-02 2018-05-09 Medigen Inc Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60335139D1 (de) * 2002-05-17 2011-01-05 Univ Emory Virusähnliche partikel, verfahren zur herstellung und immunogene zusammensetzungen
RU2535365C2 (ru) * 2007-05-29 2014-12-10 Кристофер Б РЕЙД Способы получения и применения мультипотентных клеточных популяций
WO2015066715A1 (en) * 2013-11-04 2015-05-07 Viracell Advanced Products, Llc Virus-like particles and methods related thereto

Also Published As

Publication number Publication date
CN108348596A (zh) 2018-07-31
JP2020198893A (ja) 2020-12-17
US20230310579A1 (en) 2023-10-05
US12303560B2 (en) 2025-05-20
MA42312A (fr) 2018-05-09
WO2017004586A1 (en) 2017-01-05
MX2018000023A (es) 2018-08-15
RU2020125098A3 (enExample) 2020-12-11
BR112018000037A2 (pt) 2018-09-04
CN108348596B (zh) 2022-08-23
CA2991213A1 (en) 2017-01-05
CN115927212A (zh) 2023-04-07
RU2018103757A (ru) 2019-08-05
JP2018525028A (ja) 2018-09-06
EA201890187A1 (ru) 2018-06-29
RU2020125098A (ru) 2020-09-04
RU2734118C2 (ru) 2020-10-13
US20180369364A1 (en) 2018-12-27
KR20180032586A (ko) 2018-03-30
EP3316906A1 (en) 2018-05-09
RU2018103757A3 (enExample) 2019-12-09
EP3316906A4 (en) 2019-01-02
PE20180771A1 (es) 2018-05-07
HK1259067A1 (zh) 2019-11-22
JP6978079B2 (ja) 2021-12-08
US11576965B2 (en) 2023-02-14
MX390927B (es) 2025-03-21

Similar Documents

Publication Publication Date Title
US12303560B2 (en) Recombinant bovine immunodeficiency virus-like particles comprising an influenza HA transmembrane domain and C-terminus
Tretyakova et al. Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses
Kapczynski et al. Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses
US10369211B2 (en) Influenza H5 vaccines
Pushko et al. Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone
US12102674B2 (en) Universal influenza vaccine
US20240100148A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
US20160361409A1 (en) H5 proteins of h5n1 influenza virus for use as a medicament
HK40090606A (zh) 用牛免疫缺陷病毒gag蛋白的重组病毒样颗粒
EA042635B1 (ru) Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита
TWI390038B (zh) 流感病毒重組ｈａ似病毒顆粒及其疫苗組成物
HK1259067B (en) Recombinant virus like particles using bovine immunodeficiency virus gag protein
US20230055468A1 (en) Broadly reactive viral antigens as immunogens, compositions and methods of use thereof
Shehata Truncated Sequences of Influenza Subtype H5 Haemagglutinin for Vaccination and Diagnostic Purposes: Avian influenza, Yeast expression, Peptide vaccination, recombinant Elisa